Ocugen (NASDAQ:OCGN) Issues Quarterly Earnings Results

Ocugen (NASDAQ:OCGN) posted its earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01), Zacks reports. The business had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $0.42 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%.

Here are the key takeaways from Ocugen’s conference call:

• Ocugen announced a $115 million convertible senior notes offering expected to close May 7, which management says would bring expected cash equivalents and restricted cash to $112.1 million (or $127.1 million if remaining warrants are exercised) and extend cash runway into 2028.
• Phase II data for OCU410 (GA) showed the medium dose produced a 31% reduction in lesion growth at 12 months versus control (p<0.05), ~2x the treatment effect of approved intravitreal therapies, with a favorable tolerability profile after a single one‑time subretinal injection.
• OCU400 (RP) completed enrollment in the 140‑patient LIMELIGHT Phase III trial, plans to begin a rolling BLA in Q3 2026, expects Phase III top‑line in Q1 2027 and potential approval targeted for Q4 2027, and cites durable 3‑year benefit and no drug‑related SAEs in earlier cohorts.
• OCU410ST (Stargardt) dosing in the pivotal GARDian3 trial finished ahead of schedule (63 patients); an interim outcome analysis is planned for Q3 2026 with top‑line data expected in Q2 2027 and a potential BLA mid‑2027, but the adaptive DMC review could require sample‑size adjustments and timing changes.
• Financials show rising spend and ongoing losses — Q1 operating expenses rose to $19.4 million with a $0.06 net loss per share and cash of $32.2 million as of March 31, 2026 (pre‑financing), meaning execution depends on the planned financing and future regulatory outcomes and may involve dilution or additional funding needs.

Ocugen Stock Down 1.7%

Shares of NASDAQ OCGN traded down $0.03 during trading on Wednesday, reaching $1.47. 9,953,394 shares of the stock were exchanged, compared to its average volume of 7,701,474. The business’s 50-day moving average price is $1.88 and its 200 day moving average price is $1.59. Ocugen has a twelve month low of $0.64 and a twelve month high of $2.73. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 8.04. The company has a market capitalization of $495.93 million, a price-to-earnings ratio of -6.37 and a beta of 2.30.

Trending Headlines about Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Positive late‑stage clinical update — Ocugen reported statistically significant 12‑month Phase 2 OCU410 (ArMaDa) results for geographic atrophy (noted >30% lesion‑growth reduction vs control), says enrollment is complete for key registrational trials and the company targets two BLA submissions by 2027, which materially raises the commercial pathway risk/reward if Phase 3 confirms results. Ocugen Provides Business Update with First-Quarter 2026 Financial Results
• Positive Sentiment: Cash runway extension / deleveraging — Ocugen priced $115M of 6.75% convertible senior notes, expects ~ $99.5M net proceeds and plans to use ≈$32.7M to repay a high‑interest Avenue loan, which should reduce near‑term interest burden and extend runway into 2028 per management. Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
• Neutral Sentiment: Analyst stance — Recent aggregation shows a consensus “Moderate Buy,” which can support investor sentiment but contrasts with elevated risk and potential dilution. Ocugen Receives Consensus Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Mixed Q1 results — Q1 EPS of ($0.06) missed estimates by $0.01 while revenue of $1.53M comfortably beat consensus; management commentary highlighted trial progress but losses widened, keeping near‑term fundamentals under pressure. Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
• Negative Sentiment: Dilution and new leverage risk — The notes carry 6.75% interest, were priced at 90% of par, and convert at ~$2.68/share (≈45% premium). Conversion features and potential future share issuance create dilution risk if converted; the financing also signals reliance on capital markets. Ocugen Announces Pricing of $115 Million Convertible Senior Notes Offering
• Negative Sentiment: Market reaction to earnings — Coverage noted the widened Q1 loss and the EPS miss, which has pressured the share price despite the revenue beat and clinical progress. Ocugen stock dips as Q1 losses widen

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SmartHarvest Portfolios LLC acquired a new position in shares of Ocugen during the fourth quarter worth $31,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Ocugen during the fourth quarter worth $38,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Ocugen by 28,222.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock worth $41,000 after purchasing an additional 30,198 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Ocugen by 198.0% during the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock worth $36,000 after purchasing an additional 24,460 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after purchasing an additional 13,326 shares in the last quarter. 10.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on OCGN. Wall Street Zen downgraded shares of Ocugen from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Ocugen in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Ocugen in a report on Thursday, January 22nd. Oppenheimer began coverage on shares of Ocugen in a report on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 target price for the company. Finally, Canaccord Genuity Group began coverage on shares of Ocugen in a research report on Tuesday, March 17th. They set a “buy” rating and a $12.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.